EP Patent

EP3321270B1 — Sodium (2r, 5s, 13ar)-7, 9-dioxo-10- ((2,4,6-trifluorobenzyl)carbamoyl)-2, 3, 4, 5, 7, 9, 13,13a-octahydro-2,5-methanopyrido [1',2':4.5] pyrazino [2, 1-b] oxazepin-8-olate

Assigned to Gilead Sciences Inc · Expires 2024-12-04 · 1y expired

What this patent protects

Patent listed against bictegravir-sodium.

Drugs covered by this patent

bictegravir-sodium (BICTEGRAVIR SODIUM)

Patent Metadata

Patent number: EP3321270B1
Jurisdiction: EP
Classification: —
Expires: 2024-12-04
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.